

Short Communication

Screening of Two Neighboring *CFTR* Mutations in Iranian Infertile Men with Non-Obstructive Azoospermia

Somayeh Heidari, M.Sc., Zohreh Hojati, Ph.D., Majid Motovali-Bashi, Ph.D.

Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran

Abstract

The genetic association between cystic fibrosis transmembrane conductance regulator (*CFTR*) gene mutations and male infertility due to congenital bilateral absence of vas deferens (CBAVD) is well established. Mutant *CFTR*, however may also be involved in the etiology of male infertility in non-CBAVD cases. The present study was conducted to estimate the frequency of $\Delta I507$ and $\Delta F508$ *CFTR* gene mutations in Iranian infertile males. We undertook the first study of association between these *CFTR* mutations and non-obstructive azoospermia in Iran.

In this case-control study, 100 fertile healthy fathers and 100 non-obstructive azoospermia's men were recruited from Isfahan Infertility Center (IIC) and Sari Saint Mary's Infertility Center, between 2008 and 2009. Screening of F508del and I507del mutations was carried out by the multiplex-ARMS-PCR. Significance of differences in mutation frequencies between the patient and control groups was assessed by Fisher's exact test. The $\Delta F508$ was detected in three patients. However there are no significant association was found between the presence of this mutated allele and infertility [OR=9.2 (allele-based) and 7.2 (individual-based), P=0.179]. None of the samples carried the $\Delta I507$ mutation. Altogether, we show that neither $\Delta I507$ nor $\Delta F508$ is involved in this population of Iranian infertile males with non-obstructive azoospermia.

Keywords: *CFTR*, Mutation, Azoospermia, Male Infertility

Citation: Heidari S, Hojati Z, Motovali-Bashi M. Screening of two neighboring *CFTR* mutations in Iranian infertile men with non-obstructive azoospermia. *Int J Fertil Steril.* 2017; 10(4): 390-394.

Introduction

Reproductive failure is associated with various genetic disorders, mainly numerical and structural chromosome abnormalities and gene mutations. At the genic level, male infertility has been linked with protamine gene mutations (1, 2), 5-alpha reductase deficiency (3), androgen receptor gene mutations (4, 5) and cystic fibrosis transmembrane conductance regulator gene (*CFTR*) mutations (6-14). More than 1950 *CFTR* variants have been identified in different ethnic populations, as curated in the cystic fibrosis genetic analysis consortium database. Many of these mutations are associated with a wide spectrum of phenotypes, including respiratory distress, chronic pancreatitis and male infertility (11). Male infertility caused by congenital bilateral absence of vas deferens (CBAVD) has been reported in more

than 95% of men with cystic fibrosis (CF) (7, 10). The genetic association between *CFTR* mutations and male infertility due to CBAVD is well established (10-12, 15). Several studies have revealed involvement of *CFTR* mutations in other forms of male infertility due to defective spermatogenesis (10, 16-20). Although a two-five fold increased in *CFTR* mutation rate in males with non-obstructive azoospermia has been reported (REF), a number of reports did not find any association between them (10, 17, 20-23). van der Ven et al. (20) investigate the possible involvement of *CFTR* in the etiology of non-CBAVD male infertility. Semen specimens from 127 unrelated healthy males with various diagnoses of reduced sperm quality were screened for a panel of 13 *CFTR* mutations. Fourteen of 80 (17.5%) infertile men due to reduced sperm quality and 3 of

Received: 20 Dec 2015, Accepted: 24 July 2016
*Corresponding Address: P.O.Box: 81746-73441, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran
Email: z.hojati@sci.ui.ac.ir



Royan Institute
International Journal of Fertility and Sterility
Vol 10, No 4, Jan-Mar 2017, Pages: 390-394

21 (14.3%) men with azoospermia had at least one *CFTR* mutation (one azoospermic male was a compound heterozygote). No mutations were found in the control group of 26 individuals with normal semen parameters. This overrepresentation of *CFTR* mutations in men with reduced sperm quality and in men with azoospermia without CBAVD suggests that *CFTR* protein may be involved in the process of spermatogenesis or sperm maturation apart from playing a critical role in the development of epididymal glands and the vas deferens (20). Schulz et al. (10) investigated the frequency of *CFTR* mutations in 597 males with reduced sperm quality and 34 (5.70%) carried a mutation, indicating a two-fold higher frequency than in the general population. Boucher et al. (22) screened 39 patients with azoospermia without CAVD and 37 patients with severe oligozoospermia for a panel of 10 *CFTR* mutations. None of the *CFTR* mutations were observed in the patient group and suggested that *CFTR* gene is not involved in spermatogenesis.

Some studies have reported expression of the *CFTR* gene in human Sertoli cells, germ cells and testes, suggesting its possible involvement in spermatogenesis (24-26). Based on these investigations, to date, it remains uncertain whether screening of *CFTR* mutations should be recommended for infertile males with non-obstructive azoospermia during assisted reproduction technology. There are just a few studies reporting the association between *CFTR* mutations and non-obstructive azoospermia, especially in the Iran. The aim of this study was to estimate the frequency of $\Delta I507$ and $\Delta F508$ *CFTR* mutations in Iranian infertile males with non-obstructive azoospermia. We undertook the first study of association between *CFTR* gene mutations and non-obstructive azoospermia in Iran.

This study was a case-control study. Blood samples were collected from 100 males with non-obstructive azoospermia in the Isfahan Infertility Center (IIC) and Sari Saint Mary's Infertility Center, Iran, between 2008 and 2009, and from 100 normal men (men with normal fertility with at least one child and normal sperm parameters). All the patients and control individuals gave informed written consent to be included in the study. The diagnosis of non-obstructive azoospermia was based on the

following examinations: normal semen volume, normal testicular size, presence of the vas deferens by clinical examination, normal levels of serum follicle-stimulating hormone (FSH), azoospermia, absence or low levels of fructose and absence of spermatozoa in sample extracted by percutaneous testicular sperm aspiration (TESA). No symptoms of CF including chronic lung inflammation/infection, pancreatic insufficiency and intestinal obstruction were reported in the clinical files of the patients. The mean age of the patients and controls were 31.5 and 30 years, respectively. In this study, all patients were azoospermic with an absence of spermatozoa in the semen and sample extracted by TESA.

The $\Delta F508$ and $\Delta I507$ mutations in exon 10 of *CFTR* were selected for screening. The specificity of the primers were analyzed using Oligo®7 software (Version 7.0, Rychlik, 2007) (27). Further comparison of designed primers with the exon 10 sequence of *CFTR* was performed by CLC software (www.clcbio.com/genomics).

Two ml blood was collected from each patient and normal control in tubes containing EDTA. Leukocyte genomic DNA was extracted from blood samples using the standard method of salting out with slight modification (28). Genomics DNA samples were stored in -20°C after determining their relevant concentrations and quality on gels.

Multiplex-ARMS-PCR was carried out in two separate reactions. This method is schematically drawn in the Figure 1.

	Normal sequence	F508 sequence	I507 sequence
DF-N primer	←	X ←	←
DF-M primer	X ←	←	X ←
IF-N primer	→	→ X	→ X
IF-M primer	→ X	→	→

Fig.1: Visual representatin of wild-allele, $\Delta F508$ and $\Delta I507$ mutant ARMS primers for the amplification of the target sequence. The diagrams in the boxes align the normal and mutant ARMS primers (5' to 3') with the normal, $\Delta F508$, and $\Delta I507$ target DNA sequences.

Identification of *CFTR* Mutations Using Multiplex-ARMS PCR

The genotype of an individual can be determined by analysing of the amplification products. Sequences of all primers were shown in Table 1.

Table 1: List of primer sequences

Primer name	Sequences (5' to 3')
FC	GGT TTT ATT TCC AGA CTT CAC TTC ATAT
RC	TGC ATA ATC AAA AAG TTT TCA CAT AGT T
DFN	GTA TCT ATA TTC ATC ATA GGA AAC ACC ACA
DFM	GTA TCT ATA TTC ATC ATA GGA AAC ACC AAT
IFN	CTG GCA CCA TTA AAG AAA ATA TCA TCT T
IFM	CTG GCA CCA TTA AAG AAA ATA TCA TTG G

Wild-allele specific primers (DFN and FC primers) and $\Delta F508$ mutant-allele specific primers (DFM and FC primers) produce 173 bp and 170 bp fragments, respectively. Amplification of sequence by wild-allele specific primers (IFN and RC primers) and $\Delta I507$ mutant-allele specific primers (IFM and RC) give 123 bp and 120 bp fragments, respectively (Fig.2).




Fig.2: Detection of $\Delta F508$ *CFTR* mutation in infertile men by using multiplex-ARMS-PCR. The amplification products of normal primer sets are shown here (N). M indicates the amplification products by IFM and DFM primers. The resulted amplified fragments for a normal and $\Delta F508$ mutant are shown here. Sample I is a wild homozygote, sample II is a mutant homozygote ($\Delta F508$) and sample III is a heterozygote ($\Delta F508$). Fragment sizes are in the base pairs (bp). Marker; 50 bp DNA ladder. N-I; Normal primer sets for sample I, M-I; Mutant primer sets for sample I, N-II; Normal primer sets for sample II, M-II; Mutant primer sets for sample II, N-III; Normal primer sets for sample III, and M-III; Mutant primer sets for sample.

DNA amplification was carried out in duplicate for all samples. Each 25 μ l reaction mixture contained 3 μ l template DNA (50-100 ng), 1.6 μ l $MgCl_2$ (2.0 mM), 2.5 μ l 10X PCR buffer, 1.5 μ l FC (20 pmol ml^{-1}), 1.5 μ l RC (20 pmol ml^{-1}), 0.75 μ l DFN (20 pmol ml^{-1}), 0.75 μ l IFN (20 pmol ml^{-1}), 1 μ l dNTP mix (10 mM), 0.4 μ l Taq polymerase (5 U) and 12 μ l ddH_2O . The reaction mixtures were prepared and kept on ice until the heating block of the thermal cycler reached the denaturation temperature (94°C). The PCR amplification was carried out at 94°C for 10 minutes and then followed with 32 amplification cycles of 40 seconds at 94°C, 1 minute at 58.8°C, 1 minute at 72°C, and a final extension at 72°C for 10 minutes. Amplification products were separated by electrophoresis using a 2.5% Metaphor agarose gel, stained with ethidium bromide and visualized by ultraviolet illumination.

Significance of differences in mutation frequencies between the patient and control groups was assessed by Fisher's exact test (SPSS software version 16.0) and P values < 0.05 were considered statistically significant.

The percentage difference of $\Delta F508$ mutation between the patient and control groups was although not statistically significant (P=0.179), possibly due to the relatively small sample size, it displayed a large effect size [OR=9.2 (allele-based) and 7.2 (individual-based)]. No individuals carried the $\Delta I507$ mutation.

The genetic link between *CFTR* mutations and a genital form of male infertility (CBAVD) is well established. Thus, screening of *CFTR* mutations is proposed for all infertile men with CBAVD, however, the association of *CFTR* mutations and non-CBAVD male infertility, is uncertain. Recently Xu et al. (29) demonstrated *CFTR*-dependent regulation of CREB in human Sertoli cells which suggests that its defective regulation may cause spermatogenesis failure as seen in non-obstructive azoospermia. This seems to be the possible mechanism by which *CFTR* may be involved in spermatogenesis. There are a few studies which have specifically looked at the frequency and role of *CFTR* mutations in azoospermic men without CBAVD (20, 23, 30-32). Many reports to date have shown conflicting results. Some studies

showed significant association between *CFTR* mutations and non-obstructive azoospermia while the other investigations ruled out this association (14). In the present study, $\Delta F508$ mutation was observed twice in heterozygous form (2%) and once in homozygous form among the 100 non-obstructive patients. This result is consistent with previous studies. For instance, Safinejad et al. (6) evaluated five common *CFTR* mutations ($\Delta F508$, G542X, R117H, W1282X and N1303K) in Iranian infertile men with non-CAVD obstructive azoospermia. The common *CFTR* mutations were found in 9.43% (5.53%) patients for $\Delta F508$ mutation. Another study by Sharma et al. (11) analyzing the frequency of *CFTR* mutations in infertile Indian males with non-obstructive azoospermia (n=60) and spermatogenic failure (n=150), showed that $\Delta F508$ mutation was observed in 3.6% of patients with non-obstructive azoospermia.

However, some reports revealed the absence of $\Delta F508$ mutation among all infertile patients (7, 22, 33). Ravnik-Glavac et al. (23) screened 80 men with idiopathic azoospermia, 50 men with severe oligozoospermia, 70 men with oligoasthenoteratozoospermia, and 7 men with CBAVD as well as 95 controls from Slovenia for mutations in 10 *CFTR* exons where the majority of the common CF disease causing mutations have been detected. The frequencies of *CFTR* mutations did not differ significantly between the control group and men with idiopathic nonobstructive azoospermia and subfertility, suggesting that *CFTR* mutations are not associated with spermatogenic failure and non-obstructive pathology of urogenital tract in men.

Moreover, we did not observed the $\Delta I507$ mutation among all infertile patients and control individuals suggesting its rarity as a cause. In conclusion, our results did not show any significant association between these two mutations and non-obstructive azoospermia.

The studied population is informative but its size is not large enough to make definitive inferences about the involvement of these two mutations in non-obstructive azoospermia.

Further studies with greater number of *CFTR* mutations and patients are therefore needed to ex-

amine the role of *CFTR* in non-obstructive azoospermia.

Acknowledgements

This study was carried out at University of Isfahan and was financially supported by the Graduate Studies Office. The authors are grateful to the Graduate Office of the University of Isfahan for their support. We would also like to thank Isfahan Infertility Center and Sari Saint Mary's Infertility Center. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Horsthemke B, Ludwig M. Assisted reproduction: the epigenetic perspective. *Hum Reprod Update*. 2005; 11(5): 473-482.
2. Oliva R. Protamines and male infertility. *Hum Reprod Update*. 2006; 12(4): 417-435.
3. Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, Vuerich M, et al. Molecular characterization of 6 unrelated Italian patients with 5 α -reductase type 2 deficiency. *J Androl*. 2008; 29(1): 20-28.
4. Foresta C, Ferlin A, Gianaroli L, Dallapiccola B. Guidelines for the appropriate use of genetic tests in infertile couples. *Eur J Hum Genet*. 2002; 10(5): 303-312.
5. Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A. Androgen insensitivity syndrome: clinical features and molecular defects. *Hormones (Athens)*. 2008; 7(3): 217-229.
6. Safinejad K, Darbouy M, Kalantar SM, Zeinali S, Mirfakhraie R, Yadegar L, et al. The prevalence of common *CFTR* mutations in Iranian infertile men with non-CAVD obstructive azoospermia by using ARMS PCR techniques. *J Assist Reprod Genet*. 2011; 28(11): 1087-1090.
7. Ghorbel M, Baklouti-Gargouri S, Keskes R, Sellami-Ben Hamida A, Feki-Chakroun N, Bahloul A, et al. Screening of $\Delta F508$ mutation and IVS8-poly T polymorphism in *CFTR* gene in Tunisian infertile men without CBAVD. *Andrologia*. 2012; 44 Suppl 1: 376-382.
8. Lu S, Yang X, Cui Y, Li X, Zhang H, Liu J, et al. Different cystic fibrosis transmembrane conductance regulator mutations in Chinese men with congenital bilateral absence of vas deferens and other acquired obstructive azoospermia. *Urology*. 2013; 82(4): 824-828.
9. Ferlin A, Arredi B, Foresta C. Genetic causes of male infertility. *Reprod Toxicol*. 2006; 22(2): 133-141.
10. Schulz S, Jakubiczka S, Kropf S, Nickel I, Muschke P, Kleinstejn J. Increased frequency of cystic fibrosis transmembrane conductance regulator gene mutations in infertile males. *Fertil Steril*. 2006; 85(1): 135-138.
11. Sharma H, Mavuduru RS, Singh SK, Prasad R. Increased frequency of *CFTR* gene mutations identified in Indian infertile men with non-CBAVD obstructive azoospermia and spermatogenic failure. *Gene*. 2014; 548(1): 43-47.
12. Cuppens H, Cassiman JJ. *CFTR* mutations and polymorphisms in male infertility. *Int J Androl*. 2004; 27(5): 251-

Identification of *CFTR* Mutations Using Multiplex-ARMS PCR

- 256.
13. Schwarzer JU, Schwarz M. Significance of *CFTR* gene mutations in patients with congenital aplasia of vas deferens with special regard to renal aplasia. *Andrologia*. 2012; 44(5): 305-307.
 14. Chen H, Ruan YC, Xu WM, Chen J, Chan HC. Regulation of male fertility by *CFTR* and implications in male infertility. *Hum Reprod Update*. 2012; 18(6): 703-713.
 15. Yu J, Chen Z, Ni Y, Li Z. *CFTR* mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. *Hum Reprod*. 2012; 27(1): 25-35.
 16. Dohle GR, Halley DJ, Van Hemel JO, van den Ouwel AM, Pieters MH, Weber RF, et al. Genetic risk factors in infertile men with severe oligozoospermia and azoospermia. *Hum Reprod*. 2002; 17(1): 13-16.
 17. Jakubiczka S, Bettecken T, Stumm M, Nickel I, Müsebeck J, Krebs P, et al. Frequency of *CFTR* gene mutations in males participating in an ICSI programme. *Hum Reprod*. 1999; 14(7): 1833-1834.
 18. Stuppia L, Antonucci I, Binni F, Brandi A, Grifone N, Colosimo A, et al. Screening of mutations in the *CFTR* gene in 1195 couples entering assisted reproduction technique programs. *Eur J Hum Genet*. 2005; 13(8): 959-964.
 19. Tamburino L, Guglielmino A, Venti E, Chamayou S. Molecular analysis of mutations and polymorphisms in the *CFTR* gene in male infertility. *Reprod Biomed Online*. 2008; 17(1): 27-35.
 20. van der Ven K, Messer L, van der Ven H, Jeyendran RS, Ober C. Cystic fibrosis mutation screening in healthy men with reduced sperm quality. *Hum Reprod*. 1996; 11(3): 513-517.
 21. Cruger DG, Agerholm I, Byriel L, Fedder J, Bruun-Petersen G. Genetic analysis of males from intracytoplasmic sperm injection couples. *Clin Genet*. 2003; 64(3): 198-203.
 22. Boucher D, Creveaux I, Grizard G, Jimenez C, Hermbessière J, Dastugue B. Screening for cystic fibrosis transmembrane conductance regulator gene mutations in men included in an intracytoplasmic sperm injection programme. *Mol Hum Reprod*. 1999; 5(6): 587-593.
 23. Ravnik-Glavac M, Svetina N, Zorn B, Peterlin B, Glavac D. Involvement of *CFTR* gene alterations in obstructive and nonobstructive infertility in men. *Genet Test*. 2001; 5(3): 243-247.
 24. Gong XD, Li JC, Cheung KH, Leung GP, Chew SB, Wong PY. Expression of the cystic fibrosis transmembrane conductance regulator in rat spermatids: implication for the site of action of antispermatogenic agents. *Mol Hum Reprod*. 2001; 7(8): 705-713.
 25. Hihnala S, Kujala M, Toppari J, Kere J, Holmberg C, Höglund P. Expression of *SLC26A3*, *CFTR* and *NHE3* in the human male reproductive tract: role in male subfertility caused by congenital chloride diarrhoea. *Mol Hum Reprod*. 2006; 12(2): 107-111.
 26. Boockfor FR, Morris RA, DeSimone DC, Hunt DM, Walsh KB. Sertoli cell expression of the cystic fibrosis transmembrane conductance regulator. *Am J Physiol*. 1998; 274(4 Pt 1): C922-930.
 27. Rychlik W. OLIGO 7 primer analysis software. *Methods Mol Biol*. 2007; 402: 35-60.
 28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988; 16(3): 1215.
 29. Xu WM, Chen J, Chen H, Diao RY, Fok KL, Dong JD, et al. Defective *CFTR*-dependent CREB activation results in impaired spermatogenesis and azoospermia. *PLoS One*. 2011; 6(5): e19120.
 30. Meng MV, Black LD, Cha I, Ljung BM, Pera RA, Turek PJ. Impaired spermatogenesis in men with congenital absence of the vas deferens. *Hum Reprod*. 2001; 16(3): 529-533.
 31. Tuerlings JH, Mol B, Kremer JA, Looman M, Meuleman EJ, te Meerman GJ, et al. Mutation frequency of cystic fibrosis transmembrane regulator is not increased in oligozoospermic male candidates for intracytoplasmic sperm injection. *Fertil Steril*. 1998; 69(5): 899-903.
 32. Larriba S, Bonache S, Sarquella J, Ramos MD, Giménez J, Bassas L, et al. Molecular evaluation of *CFTR* sequence variants in male infertility of testicular origin. *Int J Androl*. 2005; 28(5): 284-290.
 33. Jarvi K, Zielenski J, Wilschanski M, Durie P, Buckspan M, Tullis E, et al. Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. *Lancet*. 1995; 345(8964): 1578.